Spectrum of Neurodegeneration with Brain Iron Accumulation with PLA2G6 Variation: A Report of Three Cases from Two Families

Abstract

Neurodegeneration with brain iron accumulation consists of disorders characterized by progressive neuronal degeneration, cognitive decline, brain iron accumulation in extrapyramidal system, dentate nucleus, and gray and white matters boundary. We present a case series of PLA2G6-associated neurodegeneration (PLAN), with definite PLA2G6 gene mutations in two cases and suspected in one case. Diagnosis was based on clinical presentations, brain magnetic resonance imaging (MRI) findings, and detection of PLA2G6 mutations. Case 1: An 8-year-old boy presented with weakness of lower limbs, subnormal intelligence, scanning speech, spasticity, dysdiadochokinesia, pendular knee jerk, and extensor plantar reflex. MRI of the brain showed diffuse cerebellar atrophy and white matter T2 hyperintensity with iron deposition in bilateral globus pallidi. Case 2: Elder sister of Case 1, who developed ataxia at the age of 6 years and became bedridden at 14 years. She had nocturnal enuresis, seizures, cervical dystonia, dysphagia, and died at 23 years of age. MRI showed cerebral and cerebellar atrophies and iron deposition in basal ganglia and substantia nigra. Case 3 had infantile onset with quadriparesis, optic atrophy, developmental delay, cerebral and cerebellar atrophies, and brain iron accumulation in basal ganglia. Case 1 revealed two heterozygous mutations of PLA2G6 gene in exons 16 (c.2264G > A, p. Arg755Gln) and 12 (c.1637G > A, p. Arg546Gln), classified as likely pathogenic. Elder sister (Case 2) could not be tested for this mutation. Case 3 showed homozygous silent splice site point variation in exon 7 (c.1077 G > A; p. Ser 359 Ser) of PLA2G6 gene. Thus, in patients presenting with neurodegeneration and imaging findings of brain iron accumulation, diagnosis can be established by PLA2G6 gene mutation analysis.

Keywords

neurodegeneration - brain iron accumulation - PLA2G6 gene mutations

Publication History

Received: 21 April 2022

Accepted: 20 September 2022

Article published online:
15 November 2022

• References

• 1 Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation disorders overview. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR. eds. GeneReviews. Seattle: University of Washington; 2014
• 2 Illingworth MA, Meyer E, Chong WK. et al. PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease. Mol Genet Metab 2014; 112 (02) 183-189
• 3 Khateeb S, Flusser H, Ofir R. et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet 2006; 79 (05) 942-948
• 4 Kurian MA, Morgan NV, MacPherson L. et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70 (18) 1623-1629
• 5 Gregory A, Kurian MA, Maher ER. et al. PLA2G6-Associated Neurodegeneration. June 19, 2008 (updated March 23, 2017). In: Adam MP, Mirzaa GM, Pagon RA. eds. GeneReviews® [Internet]. Seattle (WA): University of Washington; , Seattle; 1993-2022
• 6 Magrinelli F, Mehta S, Di Lazzaro G. et al. Dissecting the phenotype and genotype of PLA2G6-related parkinsonism. Mov Disord 2022; 37 (01) 148-161
• 7 Gregory A, Westaway SK, Holm IE. et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71 (18) 1402-1409
• 8 Paisan-Ruiz C, Bhatia KP, Li A. et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009; 65 (01) 19-23
• 9 Paisán-Ruiz C, Li A, Schneider SA. et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2012; 33 (04) 814-823
• 10 Lu CS, Lai SC, Wu RM. et al. PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2012; 159B [phone]
• 11 Chu YT, Lin HY, Chen PL, Lin CH. Genotype-phenotype correlations of adult-onset PLA2G6-associated neurodegeneration: case series and literature review. BMC Neurol 2020; 20 (01) 101
• 12 Guo YP, Tang BS, Guo JF. PLA2G6-associated neurodegeneration (PLAN): review of clinical phenotypes and genotypes. Front Neurol 2018; 9: 1100
• 13 Ganapathy A, Mishra A, Soni MR. et al. Multi-gene testing in neurological disorders showed an improved diagnostic yield: data from over 1000 Indian patients. J Neurol 2019; 266 (08) 1919-1926
• 14 Riku Y, Ikeuchi T, Yoshino H. et al. Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site. Acta Neuropathol Commun 2013; 1: 12
• 15 Kruer MC, Boddaert N, Schneider SA. et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol 2012; 33 (03) 407-414
• 16 Iankova V, Karin I, Klopstock T, Schneider SA. Emerging disease-modifying therapies in neurodegeneration with brain iron accumulation (NBIA) disorders. Front Neurol 2021; 12: 629414
• 17 Karin I, Büchner B, Gauzy F, Klucken A, Klopstock T. Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON)-an international network on care and research for patients with neurodegeneration with brain iron accumulation (NBIA). Front Neurol 2021; 12: 642228
• 18 Cossu G, Abbruzzese G, Matta G. et al. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. Parkinsonism Relat Disord 2014; 20 (06) 651-654
• 19 Kinghorn KJ, Castillo-Quan JI. Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation. Rare Dis 2016; 4 (01) e1128616
• 20 Clinical Trials. Desipramine in Infantile Neuroaxonal Dystrophy (INAD). 2018 Accessed November 12, 2020 at: https://clinicaltrials.gov/ct2/show/NCT03726996
• 21 Whaler S. Novel Therapeutic Strategies in NBIA: A Gene Therapy Approach for PLA2G6-Associated Neurodegeneration (Dissertation). London: University College London; 2018